Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study

Rémi Goupil, Mehdi Benlarbi, William Beaubien-Souligny, Annie-Claire Nadeau-Fredette, Debashree Chatterjee, Guillaume Goyette, Caroline Lamarche, Alexander Tom, Andrés Finzi, Rita S. Suri on behalf of the Réseau Rénal Québécois (Quebec Renal Network) COVID-19 Study Investigators
doi: https://doi.org/10.1101/2021.03.30.21254652

Data Availability

De-identified aggregate data is available upon request to the lead author, RS (rita.sur{at}mcgill.ca), provided the necessary institutional approvals are received. Further information on the assays used and requests for reagents should be directed to and will be fulfilled by AF (andres.finzi{at}umontreal.ca).

Back to top
Posted April 08, 2021.
Download PDF
Data/Code
Email
Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study
Rémi Goupil, Mehdi Benlarbi, William Beaubien-Souligny, Annie-Claire Nadeau-Fredette, Debashree Chatterjee, Guillaume Goyette, Caroline Lamarche, Alexander Tom, Andrés Finzi, Rita S. Suri
medRxiv 2021.03.30.21254652; doi: https://doi.org/10.1101/2021.03.30.21254652
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area